Euro panel backs Merck’s Keytruda + Pfizer’s Inlyta in first-line kidney cancer

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of the combination of Merck’s (NYSE:MRK) Keytruda (pembrolizumab) and Pfizer’s (NYSE:PFE) Inlyta (axitinib) for the first-treatment of advanced renal cell carcinoma.

A final decision from the European Commission usually takes ~60 days.

MRK is up 1% premarket. This morning is also announced positive data from a late-stage study of Keytruda in triple-negative breast cancer.

https://seekingalpha.com/news/3482653-european-advisory-group-backs-mercks-keytruda-pfizers-inlyta-first-line-kidney-cancer

Edit